Skip to content
10-Q

Quarterly Report

ENTASIS THERAPEUTICS HOLDINGS INC.

0001558370-22-006098

← back to feed
Filed
Apr 27, 2022 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2022 · Apr 22, 2022 47.85M sh
Shares Diluted Q1 2022 · Mar 31, 2022 47.85M sh
Shares Diluted Q1 2022 · Mar 31, 2021 37.08M sh
Capex Q1 2022 · Mar 31, 2022 $9K
Capex Q1 2022 · Mar 31, 2021 $11K
Operating Cash Flow Q1 2022 · Mar 31, 2022 −$13.75M
Operating Cash Flow Q1 2022 · Mar 31, 2021 −$10.1M
Cash And Equivalents Q1 2022 · Mar 31, 2022 $33.55M
Cash And Equivalents Q1 2022 · Dec 31, 2021 $32.31M
Stockholders Equity Q1 2022 · Mar 31, 2022 $16.65M
Stockholders Equity Q1 2022 · Dec 31, 2021 $31.21M
Stockholders Equity Q1 2022 · Mar 31, 2021 $44.26M
Stockholders Equity Q1 2022 · Dec 31, 2020 $52.29M
Current Liabilities Q1 2022 · Mar 31, 2022 $24.14M
Current Liabilities Q1 2022 · Dec 31, 2021 $9.71M
Total Liabilities Q1 2022 · Mar 31, 2022 $27.44M
Total Liabilities Q1 2022 · Dec 31, 2021 $9.71M
Current Assets Q1 2022 · Mar 31, 2022 $39.88M
Current Assets Q1 2022 · Dec 31, 2021 $39.82M
Total Assets Q1 2022 · Mar 31, 2022 $44.09M
Total Assets Q1 2022 · Dec 31, 2021 $40.92M
Eps Diluted Q1 2022 · Mar 31, 2022 −$0.32
Eps Diluted Q1 2022 · Mar 31, 2021 −$0.29
Eps Basic Q1 2022 · Mar 31, 2022 −$0.32
Eps Basic Q1 2022 · Mar 31, 2021 −$0.29
Sga Expense Q1 2022 · Mar 31, 2022 $4.94M
Sga Expense Q1 2022 · Mar 31, 2021 $3.31M
Rd Expense Q1 2022 · Mar 31, 2022 $10.99M
Rd Expense Q1 2022 · Mar 31, 2021 $9.37M
Net Income Q1 2022 · Mar 31, 2022 −$15.26M
Net Income Q1 2022 · Mar 31, 2021 −$10.7M
Operating Income Q1 2022 · Mar 31, 2022 −$15.93M
Operating Income Q1 2022 · Mar 31, 2021 −$12.68M